<DOC>
	<DOCNO>NCT01319331</DOCNO>
	<brief_summary>The purpose study determine drug Alpha-1 Antitrypsin ( AAT , Aralast NP ) preserve beta-cell function help slow progression type 1 diabetes .</brief_summary>
	<brief_title>The Effects Alpha-1 Antitrypsin ( AAT ) Progression Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Diagnosis Type 1 Diabetes Mellitus base ADA Criteria few 5 year 100 day 645 year age , inclusive . To assess safety , initially enroll 8 patient age 16 . Following last infusion 8th patient , assess adverse event . As long stop criterion meet 8 patient decrease age criterion 6 year old . Cpeptide increase screen mixed meal tolerance test minimal stimulate value ≥ 0.2 pmol/mL . Positive antibody insulin ( insulin autoantibody positive , determination must within two week insulin initiation ) , GAD65 , IA2 ZnT8 Agree intensive management diabetes HgbA1c goal &lt; 7.0 % If female , ( ) surgically sterile ( b ) postmenopausal ( c ) reproductive potential , willing use medically acceptable birth control ( e.g . female hormonal contraception , barrier method sterilization . ) 3 month completion treatment period If male reproductive potential , willing use medically acceptable birth control 3 month completion treatment period , unless female partner postmenopausal surgically sterile Serum creatinine ≤ 1.5 x upper limit normal AST &lt; 2 time upper limit normal Hematology : WBC &gt; 3000 x 109/L ; platelet &gt; 100 x 109/L ; hemoglobin &gt; 10.0 g/dL . Unable unwilling comply requirement study protocol Body Mass Index ( BMI ) &gt; 30 kg/m2 Unstable blood sugar control define one episode severe hypoglycemia ( define hypoglycemia require assistance another person ) within last 30 day Previous immunotherapy T1D Administration experimental agent T1D time use experimental device T1D within 30 day screen , unless approve study PI History organ transplant , include islet cell transplant Active autoimmune immune deficiency disorder ( e.g . sarcoidosis , rheumatoid arthritis ) Serum bilirubin &gt; ULN , except subject whose abnormal value attribute stable , benign condition ( Gilbert 's Syndrome ) may include TSH outside normal range screening , except subject stable dos thyroid hormone replacement therapy may include Known HIV positivity , active hepatitis B active hepatitis C infection Anticipated pregnancy active dosing within 3 month completion active dose phase History malignant neoplasm within previous 5 year ( except situ cervical cancer curable nonmelanoma skin malignancy ) Any social condition medical condition would , opinion investigator , prevent complete participation study would pose significant hazard subject ' participation History active substance abuse within 12 month screen A psychiatric medical disorder would prevent give informed consent Individuals history IgA deficiency Individuals history hypersensitivity AAT</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>diabetes</keyword>
	<keyword>type 1 diabetes</keyword>
	<keyword>AAT</keyword>
	<keyword>Alpha-1 Antitrypsin</keyword>
</DOC>